

GAN 1644
BOX SEQ
PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

February 22, 2000
Date

Lawrence Teague
Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gaiger and Martin A. Cheever
Application No. : 09/164,223
Filed : September 30, 1998
For



COMPOSITIONS AND METHODS FOR WT1 SPECIFIC
IMMUNOTHERAPY

Examiner : Ron Schwadron, Ph.D.
Art Unit : 1644
Docket No. : 210121.465
Date : February 22, 2000

MAR 02 2000

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO THE COMMUNICATION FROM THE EXAMINER

Sir:

In response to the Communication from the Examiner dated December 20, 1999, please find enclosed a check, a computer diskette containing a copy of the Sequence Listing in computer readable format, an Amendment Regarding Sequence Disclosures, a declaration regarding the computer diskette, a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, an amendment, a paper copy of the Sequence Listing, and a Petition for Extension of Time plus two copies.

Respectfully submitted,
Alexander Gaiger and Martin A. Cheever
Seed Intellectual Property Law Group PLLC

Stephen J. Rosenman
Stephen J. Rosenman, Ph.D.
Registration No. 43,058

DJM:ljt

Enclosures:

Postcard
Check No. 10537 for \$55
Computer Diskette
Amendment Regarding Sequence Disclosures
Declaration Regarding Computer Diskette
Paper Copy of the Sequence Listing
Copy of Notice to Comply
Petition for Extension of Time (+2)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
(206) 622-4900
Fax: (206) 682-6031

ljtsequence new rule\210121\465.rms

RECEIVED
MAR -6 2000
TC 1600 MAIL ROOM



Application No.: 09164223

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: SEE ENCLOSED NOTE

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE